GlassScriptPhysician profile
Scott Alan Dorroh
NPI 1124231816
$6,473.98
in general payments reported to CMS, 2019-2025
66 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $301 · 2021: $202 · 2022: $944 · 2023: $1,098 · 2024: $1,669 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.83 |
| Education | $133.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $492.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $424.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $372.85 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $303.82 | 2019-2025 | Imfinzi, Enhertu |
| Sumitomo Pharma America, INC. | $300.23 | 2023-2025 | Orgovyx |
| Medtronic, INC. | $296.37 | 2022-2025 | Osteocool Rf Ablation System, Signia |
| Exelixis INC. | $289.48 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $275.29 | 2019-2025 | Enhertu, Injectafer |
| Abbvie INC. | $242.06 | 2019-2025 | Venclexta |
| Incyte Corporation | $229.41 | 2019-2025 | Jakafi, Monjuvi |
| Amgen INC. | $210.64 | 2019-2025 | Evenity, Prolia, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $191.11 | 2019-2024 | Opdualag |
| Eisai INC. | $175.31 | 2019-2025 | |
| Genzyme Corporation | $167.00 | 2019-2025 | |
| Genentech USA, INC. | $164.81 | 2019-2023 | Perjeta, Phesgo, Venclexta |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dorroh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.